Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer : Current perspectives and Moving Forward
© 2023 Shinada and Murakami..
Perioperative therapy for non-small cell lung cancer has been studied extensively in a bid to improve overall survival, as approximately half of the patients with surgically resectable tumors at the time of diagnosis relapse. In recent years, immune checkpoint inhibitor therapies, such as the anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, have contributed to achieving an improved overall survival of patients with advanced stage lung cancer. Thus, the development of this treatment strategy has considerable potential to precipitate a breakthrough in cancer immunotherapy. PD-1/PD-L1 blockade has several potential immunological benefits when used as a neoadjuvant therapy. However, there are concerns associated with this neoadjuvant therapy. Many studies have reported its efficacy, but there is limited evidence regarding the long-term survival of patients. Similarly, it is unclear whether existing biomarkers are adequate for monitoring the prognosis of patients, or if new biomarkers are required. In this article, we present recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discuss its future challenges.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
OncoTargets and therapy - 16(2023) vom: 14., Seite 99-108 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shinada, Kanako [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ICI |
|---|
| Anmerkungen: |
Date Revised 24.02.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/OTT.S399657 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353212253 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353212253 | ||
| 003 | DE-627 | ||
| 005 | 20231226055504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/OTT.S399657 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353212253 | ||
| 035 | |a (NLM)36814961 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shinada, Kanako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer |b Current perspectives and Moving Forward |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Shinada and Murakami. | ||
| 520 | |a Perioperative therapy for non-small cell lung cancer has been studied extensively in a bid to improve overall survival, as approximately half of the patients with surgically resectable tumors at the time of diagnosis relapse. In recent years, immune checkpoint inhibitor therapies, such as the anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, have contributed to achieving an improved overall survival of patients with advanced stage lung cancer. Thus, the development of this treatment strategy has considerable potential to precipitate a breakthrough in cancer immunotherapy. PD-1/PD-L1 blockade has several potential immunological benefits when used as a neoadjuvant therapy. However, there are concerns associated with this neoadjuvant therapy. Many studies have reported its efficacy, but there is limited evidence regarding the long-term survival of patients. Similarly, it is unclear whether existing biomarkers are adequate for monitoring the prognosis of patients, or if new biomarkers are required. In this article, we present recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discuss its future challenges | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ICI | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a neoadjuvant | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a programmed death 1 | |
| 650 | 4 | |a programmed death ligand 1 | |
| 700 | 1 | |a Murakami, Shuji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t OncoTargets and therapy |d 2008 |g 16(2023) vom: 14., Seite 99-108 |w (DE-627)NLM199447950 |x 1178-6930 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g day:14 |g pages:99-108 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/OTT.S399657 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |b 14 |h 99-108 | ||